CO4930269A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
CO4930269A1
CO4930269A1 CO97063174A CO97063174A CO4930269A1 CO 4930269 A1 CO4930269 A1 CO 4930269A1 CO 97063174 A CO97063174 A CO 97063174A CO 97063174 A CO97063174 A CO 97063174A CO 4930269 A1 CO4930269 A1 CO 4930269A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
pharmaceutically acceptable
safe
effective amount
therapeutically effective
Prior art date
Application number
CO97063174A
Other languages
English (en)
Inventor
Goodson Gary Wayne
Wood Allen Wayne
Katherine Jeannette Ford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4930269A1 publication Critical patent/CO4930269A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una composición farmacéutica, que comprende:i) una cantidad segura y terapéuticamente efectiva de lamivudina o un derivado farmacéuticamente aceptable de la misma;ii) una cantidad segura y terapéuticamente efectiva de zidovudina o un derivado farmacéuticamente aceptable de la misma; yiii) un lubricante farmacéuticamente aceptable.
CO97063174A 1996-10-31 1997-10-28 Composiciones farmaceuticas CO4930269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CO4930269A1 true CO4930269A1 (es) 2000-06-27

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97063174A CO4930269A1 (es) 1996-10-31 1997-10-28 Composiciones farmaceuticas

Country Status (44)

Country Link
EP (1) EP0941100B1 (es)
JP (1) JP2001502718A (es)
KR (1) KR100551652B1 (es)
AP (1) AP1067A (es)
AR (1) AR009135A1 (es)
AT (1) ATE241364T1 (es)
AU (1) AU736607B2 (es)
BG (1) BG64541B1 (es)
BR (1) BR9712614A (es)
CA (1) CA2270174A1 (es)
CO (1) CO4930269A1 (es)
CY (1) CY2485B1 (es)
CZ (1) CZ296080B6 (es)
DE (1) DE69722433T2 (es)
DK (1) DK0941100T3 (es)
EA (1) EA002437B1 (es)
EE (1) EE03806B1 (es)
ES (1) ES2200204T3 (es)
GB (1) GB9622681D0 (es)
GE (1) GEP20022735B (es)
GT (1) GT199700116A (es)
HK (1) HK1020880A1 (es)
HR (1) HRP970569B1 (es)
HU (1) HU224969B1 (es)
ID (1) ID18698A (es)
IL (1) IL129422A0 (es)
IS (1) IS5024A (es)
MY (1) MY119513A (es)
NO (1) NO317163B1 (es)
NZ (1) NZ335153A (es)
OA (1) OA11038A (es)
PA (1) PA8441101A1 (es)
PE (1) PE10099A1 (es)
PL (1) PL190349B1 (es)
PT (1) PT941100E (es)
SI (1) SI0941100T1 (es)
SK (1) SK284286B6 (es)
SV (1) SV1997000090A (es)
TR (1) TR199900950T2 (es)
UA (1) UA64725C2 (es)
UY (1) UY24766A1 (es)
WO (1) WO1998018477A2 (es)
YU (1) YU19999A (es)
ZA (1) ZA979726B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
MXPA04010436A (es) * 2002-04-23 2005-05-27 Lupin Ltd Composiciones de accion a largo plazo que comprenden zidovudina y lamivudina.
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
JP2015509524A (ja) 2012-03-05 2015-03-30 シプラ・リミテッド ラミブジン、フェスティナビルおよびネビラピンを含んでなる抗レトロウイルス医薬組成物
EP2958563A2 (en) * 2013-02-20 2015-12-30 AbbVie Inc. Tablet dosage form comprising ritonavir and lopinavir

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
DE69206876T3 (de) * 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
GB9622681D0 (en) 1997-01-08
HK1020880A1 (en) 2000-05-26
AP9901519A0 (en) 1999-06-30
EE03806B1 (et) 2002-08-15
IL129422A0 (en) 2000-02-17
DE69722433D1 (de) 2003-07-03
WO1998018477A3 (en) 1998-06-18
ES2200204T3 (es) 2004-03-01
AP1067A (en) 2002-05-01
AU736607B2 (en) 2001-08-02
NO317163B1 (no) 2004-08-30
BG64541B1 (bg) 2005-07-29
EA199900345A1 (ru) 2000-02-28
DE69722433T2 (de) 2004-04-08
PE10099A1 (es) 1999-03-02
NO992091D0 (no) 1999-04-29
PA8441101A1 (es) 2000-05-24
OA11038A (en) 2002-02-06
AU5314298A (en) 1998-05-22
SK57599A3 (en) 2000-06-12
WO1998018477A2 (en) 1998-05-07
UY24766A1 (es) 2000-12-29
BR9712614A (pt) 1999-10-26
DK0941100T3 (da) 2003-09-01
SI0941100T1 (en) 2003-12-31
HU224969B1 (en) 2006-04-28
AR009135A1 (es) 2000-03-08
KR100551652B1 (ko) 2006-02-13
HUP0000344A3 (en) 2002-04-29
EP0941100A2 (en) 1999-09-15
ZA979726B (en) 1999-04-29
HUP0000344A2 (hu) 2001-05-28
PL333143A1 (en) 1999-11-22
MY119513A (en) 2005-06-30
EE9900175A (et) 1999-12-15
SK284286B6 (sk) 2005-01-03
HRP970569B1 (en) 2004-10-31
CZ155799A3 (cs) 1999-10-13
HRP970569A2 (en) 1998-08-31
KR20000052893A (ko) 2000-08-25
PL190349B1 (pl) 2005-11-30
IS5024A (is) 1999-04-09
PT941100E (pt) 2003-10-31
JP2001502718A (ja) 2001-02-27
ID18698A (id) 1998-04-30
CZ296080B6 (cs) 2006-01-11
YU19999A (sh) 2000-10-30
EP0941100B1 (en) 2003-05-28
SV1997000090A (es) 1998-10-07
NO992091L (no) 1999-06-29
ATE241364T1 (de) 2003-06-15
BG103435A (en) 2000-04-28
CA2270174A1 (en) 1998-05-07
EA002437B1 (ru) 2002-04-25
GEP20022735B (en) 2002-07-25
GT199700116A (es) 1999-04-22
UA64725C2 (uk) 2004-03-15
CY2485B1 (en) 2005-06-03
TR199900950T2 (xx) 1999-07-21
NZ335153A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
PT747050E (pt) Composicoes farmaceuticas que contem irbesartan
EE04091B1 (et) Koostised ja meetodid silmasisese rõhu alandamiseks
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
MX9201082A (es) Procedimiento para la preparacion de una composicion farmaceutica que comprende gases propelentes libres de cloro.
NO962606L (no) Farmasöytisk sammensetning
EE03692B1 (et) 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid
FI20095804A (fi) Bentsotiofeeniyhdisteet, välituotteet, koostumukset ja menetelmät
IS4706A (is) Lyfjasamsetningar
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
DE69415775D1 (de) Verbesserte Stielzusammensetzung
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
CO4930269A1 (es) Composiciones farmaceuticas
DE19581542T1 (de) Gaserzeugende Zusammensetzung
DE69619605D1 (de) Gasölzusammensetzung
FI973229A0 (fi) Uusi farmaseuttinen koostumus
LV11727A (lv) Farmaceitiska kompozicija
PT946567E (pt) Novos analogos da camptotecina, sua utilizacao como madicamentos e composicoes farmaceuticas que os contem
FI973280A (fi) Farmaseuttinen koostumus
AR011730A1 (es) UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
ATE183114T1 (de) Feste zusammensetzung
BR9605777A (pt) Composição farmacêutica
AU7496196A (en) Natural composition for combatting fungi
BR9605131A (pt) Composição farmacêutica
BR1100696A (pt) Composição consistindo essencialmente de um veìculo farmaceuticamente aceitável, uma prostaglandina livre e uma partìcula
LV10840A (lv) Sastavs koksnes aizsardzibai